GMP-Compliant Manufacturing of TRUCKs: CAR T Cells targeting GD2 and Releasing Inducible IL-18

GMP-Compliant Manufacturing of TRUCKs: CAR T Cells targeting GD2 and Releasing Inducible IL-18

Chimeric antigen receptor (CAR)-engineered T cells can be highly effective in the treatment of hematological malignancies, but mostly fail in the treatment of solid tumors. Thus, approaches using 4th advanced CAR T cells secreting immunomodulatory cytokines upon CAR signaling, known as TRUCKs ("...

Full description

Bibliographic Details
Main Authors: Abken, H. (Author), Aleksandrova, K. (Author), Altvater, B. (Author), Arseniev, L. (Author), Blasczyk, R. (Author), Dragon, A.C (Author), Eiz-Vesper, B. (Author), Esser, R. (Author), Glienke, W. (Author), Goudeva, L. (Author), Kloth, C. (Author), Köhl, U. (Author), Lode, H.N (Author), Martyniszyn-Eiben, A. (Author), Mertens, M. (Author), Moritz, T. (Author), Rossig, C. (Author), Schambach, A. (Author), Siebert, N. (Author), Stamopoulou, A. (Author), Zimmermann, K. (Author)
Format: Article
Language:English
Published: NLM (Medline) 2022
Subjects:
4th generation CAR
GD2-CAR
GMP
IL-18
Prodigy
TRUCK
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items